CCI
MGNX icon

Columbus Circle Investors’s MacroGenics MGNX Stock Holding History

Columbus Circle Investors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,144
Closed -$209K – 276
2016
Q1 		$209K Buy
+11,144
New +$212K ﹤0.01% 258

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Columbus Circle Investors's MGNX Position: Q2 2016 in Review

Columbus Circle Investors sold out of MacroGenics (MGNX) in Q2 2016, closing a stake of 11,144 shares — an estimated $209K sold.

Columbus Circle Investors first reported a position in MGNX in Q1 2016 and held it in 1 quarter. The position peaked at $209K in Q1 2016. 125 funds tracked by Wall St. Rank hold MGNX as of Q2 2016.

  • Columbus Circle Investors reported no remaining MacroGenics position as of Q2 2016 after selling out during the quarter.
  • Columbus Circle Investors sold 11,144 MacroGenics shares in Q2 2016, an estimated $209K.
  • Columbus Circle Investors first reported a position in MacroGenics in Q1 2016 and held it in 1 quarter.
  • Columbus Circle Investors's MacroGenics position peaked at $209K in Q1 2016.
  • 125 funds tracked by Wall St. Rank held MacroGenics as of Q2 2016.

Based on Columbus Circle Investors's 13F filing for Q2 2016, filed 2 Aug 2016.